Physician profile

Lalitha Subramanyam

Endocrinology, Diabetes & Metabolism · Irving, TX

NPI 1043476625

$478.36

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

See the full distribution for Endocrinology, Diabetes & Metabolism

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$181.94

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Lilly USA, LLC $145.66 2021-2022
Insulet Corporation $120.72 2021-2023 Omnipod
Mannkind Corporation $59.40 2019
Abbott Laboratories $56.31 2021-2023 Freestyle Libre 3
Medtronic, INC. $35.66 2023 Minimed 780g
Corcept Therapeutics $30.19 2023 Korlym
Novo Nordisk INC $16.44 2022
Merck Sharp & Dohme LLC $13.98 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Lalitha Subramanyam

$478.36

in general payments reported 2019-2025

Years
2019-2023
Top company
Lilly USA, LLC

https://glasscript.com/doctor/138550/lalitha-subramanyam

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.